ALKS

NEUTRALProduct

Alkermes plc

2026-07-09

Price

$53.78

-0.94%

Score3.5Watchlist

Signals3/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

Alkermes (ALKS) is experiencing high-conviction price discovery following standout Phase 2 Vibrance-2 data for its narcolepsy asset alixorexton and its recent addition to the Russell 2000 Dynamic Index. This fundamental shift is perfectly captured by SURGE and PERFECT_STACK technical signals, reflecting robust institutional accumulation that has driven the stock up 21.4% over the last month. Furthermore, the broader RISK_ON macro regime—characterized by ultra-low credit spreads and a market shrugging off geopolitical fears—provides an ideal liquidity backdrop for risk capital to aggressively chase idiosyncratic biotech breakouts.

Fired Signals

SURGEGOLDEN CROSSPERFECT STACKBARGAIN HUNTEREXTENSION

Key Takeaways

Actionable Thesis: Ride the institutional momentum generated by the Russell 2000 inclusion and Phase 2 narcolepsy data, supported by a massive +19.1% relative strength against the SPY.
Key Risk: Valuation friction and profit-taking after an aggressive year-to-date run, coupled with inherent regulatory and safety scrutiny surrounding the orexin drug class.
What to Watch: Monitor the $43.84 structural support level to ensure the uptrend remains intact while awaiting execution updates on the Phase 3 Brilliance trial.

← Back to 2026-07-09 View Full ALKS History →Yahoo Finance &nearr;